14.2 Drug Interactions & the Medically Compromised Patient
Key Takeaways
- For warfarin-treated patients, know the recent INR, procedure bleeding risk, and whether the physician wants interruption—many routine dental surgeries proceed without stopping warfarin when INR is in therapeutic range and local hemostasis is optimized.
- DOACs (e.g., dabigatran, rivaroxaban, apixaban, edoxaban) have shorter half-lives than warfarin; management hinges on renal function, bleeding risk of the procedure, and timing of the last dose rather than INR values.
- Antiresorptive drugs (bisphosphonates, denosumab) and some antiangiogenics raise MRONJ risk—prefer preventive dentistry before therapy, atraumatic technique, and informed consent; risk is higher with IV oncology regimens than typical oral osteoporosis doses.
- Pregnancy is not a reason to withhold necessary acute dental care; time elective care preferably in the second trimester, use FDA/label pregnancy awareness for drugs, and avoid elective radiographs/drugs when deferrable—but treat infection aggressively when present.
- High-yield interactions include metronidazole/macrolides with warfarin, epinephrine caution in uncontrolled hyperthyroid or with non-selective β-blockers (contextual), and CNS depressant stacking with opioids/sedatives.
14.2 Drug Interactions & the Medically Compromised Patient
Quick Answer: Screen medical history + drug list every visit. Warfarin: use recent INR and local hemostasis—often continue for routine oral surgery if INR is therapeutic. DOACs: time doses around bleeding risk; INR is not the guide. Bisphosphonates/denosumab: MRONJ risk → prevention, atraumatic surgery, consent. Pregnancy: treat infection; prefer second trimester for elective care; choose drugs with better safety data. Interactions that raise bleeding, sedation, or arrhythmia risk are exam favorites.
Medically compromised care is pure AFK application: identify risk, modify plan, know when to consult, and avoid catastrophic interactions. This section pairs with 14.1 (antibiotics) and with local anesthesia/analgesia chapters for epinephrine and opioid safety.
Systematic Pre-Treatment Screen
| Domain | What to capture | Why it changes dentistry |
|---|---|---|
| Cardiovascular | MI timing, angina class, HF, hypertension control, valves, stents, IE risk | Elective deferral windows, LA/epi limits, prophylaxis |
| Bleeding | Warfarin, DOACs, heparin, antiplatelets, liver disease, hemophilia, thrombocytopenia | Hemostasis plan, labs, consult |
| Endocrine | Diabetes (hypoglycemia risk), thyroid, adrenal suppression/steroids | Timing, infection risk, stress-dose concepts (selected) |
| Respiratory | Asthma, COPD, OSA | Emergency readiness, sedation caution |
| Renal / hepatic | Clearance of DOACs, local anesthetics, analgesics | Dose adjustment / drug choice |
| Bone / oncology | Bisphosphonates, denosumab, antiangiogenics, head-neck radiation | MRONJ / ORN risk |
| Pregnancy / lactation | Trimester, drugs, positioning | Timing and prescribing |
| Allergy / anaphylaxis history | True IgE vs intolerance | Antibiotic and LA choices |
| Immunosuppression | Transplant, chemo, HIV, biologics | Infection threshold, healing |
ASA physical status (I–VI) is a communication tool for anesthesia risk, not a complete medical diagnosis—but AFK expects you to recognize ASA III+ patients need tighter modification and possible physician input.
Anticoagulant Management: Warfarin and INR
Warfarin inhibits vitamin K–dependent clotting factors (II, VII, IX, X, proteins C/S). Effect is monitored with INR (international normalized ratio).
| Concept | AFK teaching |
|---|---|
| Therapeutic INR (many indications) | Often ~2.0–3.0; mechanical mitral valves may target higher (e.g., ~2.5–3.5)—know that targets are indication-specific |
| Before invasive dental surgery | Obtain a recent INR (commonly within 24–72 hours of the procedure in many protocols when values are unstable; stable patients may have a recent clinic value—exam emphasizes “know the INR,” not fly blind) |
| Routine extractions / minor oral surgery | Many guidelines support continuing warfarin when INR is within therapeutic range (often cited comfort zone ≤~3.0–3.5 for simple surgery—follow local protocol) with local measures |
| Local hemostasis | Atraumatic technique, gelatin sponge, sutures, tranexamic acid mouthwash (where used), pressure, avoid NSAIDs that add bleeding risk |
| When to consult / modify | INR supratherapeutic, complex surgery, poor local control expected, concurrent antiplatelets, liver disease |
| Do not | Empirically stop warfarin without a plan—bridging with heparin is a physician decision for selected high-thrombotic-risk patients |
High-yield interactions that raise INR / bleeding with warfarin: metronidazole, macrolides (esp. erythromycin/clarithromycin), azole antifungals, some fluoroquinolones, amiodarone, acute alcohol binge, dietary vitamin K swings. NSAIDs add antiplatelet/gastric bleeding risk even if INR unchanged.
AFK stem pattern: patient on warfarin for atrial fibrillation, INR 2.4 yesterday, needs simple extraction → proceed with local hemostasis, usually without stopping warfarin—not automatic hospital admission.
DOACs (Direct Oral Anticoagulants)
DOACs include dabigatran (direct thrombin inhibitor) and rivaroxaban, apixaban, edoxaban (factor Xa inhibitors). They have rapid onset, shorter half-lives than warfarin, and no routine INR monitoring (INR is not a valid intensity guide).
| Management principle | Detail |
|---|---|
| Low bleeding-risk procedures | Often continue DOAC or time dental work at trough (skip morning dose for some same-day plans per local guidance) |
| Higher bleeding-risk oral surgery | Hold DOAC for a drug-specific interval based on renal function and bleeding risk—coordinate with prescriber |
| Restart | Usually 24–72 h after adequate hemostasis, sooner/later depending on thrombotic vs bleeding balance |
| Reversal awareness | Idarucizumab (dabigatran); andexanet alfa (Xa inhibitors) in hospital emergency settings—not a chairside dental drug |
| Avoid | Adding unnecessary NSAIDs; poor communication about last dose time |
Exam contrast table:
| Feature | Warfarin | DOAC |
|---|---|---|
| Monitor | INR | Generally none routinely |
| Onset/offset | Slow (days) | Faster (hours) |
| Diet vitamin K | Yes interaction | Minimal |
| Renal importance | Moderate | High for dosing/hold times (esp. dabigatran) |
| Dental key | Recent INR + local control | Timing of last dose + renal + procedure risk |
Antiplatelet Therapy (Aspirin, Clopidogrel, etc.)
Patients with coronary stents, ACS history, or stroke prevention may take aspirin, P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), or dual antiplatelet therapy (DAPT).
| Principle | Teaching |
|---|---|
| Do not stop DAPT early after stenting without cardiology—stent thrombosis can be fatal | |
| Most minor dental surgery | Proceed with local hemostasis while continuing antiplatelets |
| Aspirin alone | Rarely stopped for simple extractions |
| NSAIDs | Add bleeding and cardiac considerations; prefer acetaminophen when antiplatelet/anticoagulant burden is high |
Bisphosphonates, Denosumab, and MRONJ
Medication-related osteonecrosis of the jaw (MRONJ) is exposed bone in the maxillofacial region persisting >8 weeks in a patient treated with antiresorptive or antiangiogenic agents, without history of radiation to the jaws (ORN is the radiation analog).
| Risk factor | Relative impact |
|---|---|
| IV bisphosphonates / denosumab for malignancy | Highest risk |
| Oral bisphosphonates for osteoporosis | Lower absolute risk, still real—duration matters |
| Tooth extraction / dentoalveolar surgery | Major local trigger |
| Infection, ill-fitting dentures, periodontitis | Contribute |
| Concomitant steroids, antiangiogenics, smoking, diabetes | Raise risk |
Clinical approach (AFK)
- Prevention: complete urgent dental care before starting IV antiresorptives when possible; optimize hygiene; avoid elective extractions during high-risk therapy when alternatives exist.
- If extraction unavoidable: informed consent for MRONJ, atraumatic technique, primary closure when feasible, chlorhexidine, close follow-up; consider drug holiday only with prescribing physician—not a unilateral dental decision.
- Established MRONJ: infection control, chlorhexidine, antibiotics when infected, conservative sequestrectomy vs more extensive surgery per stage; specialist referral.
- Implants: caution and shared decision-making in antiresorptive users—not automatic absolute ban in low-risk oral osteoporosis, but risk counseling required.
Drug holiday myth: stopping oral bisphosphonates briefly does not instantly restore bone physiology; decisions are individualized with the physician.
Pregnancy: Care Timing and Drug Awareness
Pregnancy is a physiologic stress state—not a reason to neglect odontogenic infection (infection and pain harm mother and fetus more than properly delivered dental care).
| Topic | Practical rule |
|---|---|
| Elective care | Prefer second trimester |
| Urgent/emergent care | Any trimester—treat infection, abscess, trauma |
| Positioning | Avoid prolonged supine hypotension in late pregnancy (left lateral tilt) |
| Radiographs | Use when diagnostic need exists; lead apron + thyroid collar; do not withhold necessary images |
| Local anesthetics | Lidocaine with epinephrine commonly considered acceptable when indicated; aspirate; minimize dose |
| Analgesics | Acetaminophen generally preferred; NSAIDs avoid especially third trimester (ductus arteriosus concerns); opioids only if necessary short-term |
| Antibiotics | Penicillins and cephalosporins generally favored when needed; metronidazole caution especially early; tetracyclines contraindicated (tooth discoloration, bone effects) |
| Sedation/N2O | Minimize; consult obstetric context for elective use |
Pregnancy drug awareness (historical FDA categories → modern PLLR labeling)
Older FDA letter categories (A, B, C, D, X) still appear in exam teaching even as labels move to narrative Pregnancy and Lactation Labeling Rule (PLLR) language. Use categories as a risk communication shorthand, not a substitute for current product monographs:
| Legacy category | Meaning (classic teaching) | Dental examples (generalized) |
|---|---|---|
| A | Adequate human data, no demonstrated risk | Few drugs |
| B | Animal OK / limited human concern | Many penicillins, lidocaine often taught here |
| C | Animal risk or no studies; use if benefit > risk | Some common drugs fall here |
| D | Human risk evidence; reserve for life-threatening need | Some anticonvulsants, etc. |
| X | Contraindicated in pregnancy | Warfarin (except rare mechanical-valve scenarios under specialist care), isotretinoin, etc. |
AFK attitude: choose drugs with the best pregnancy safety record; treat infection; coordinate with obstetric provider for complex cases.
Other High-Yield Medical Modifications
| Condition | Dental modification |
|---|---|
| Uncontrolled hypertension / recent MI | Defer elective care; limit epinephrine; stress reduction; emergency drugs ready |
| Asthma | Patient brings inhaler; avoid triggers; careful NSAIDs in sensitive asthmatics |
| Diabetes | Morning appointments after usual meals/meds; source control for infection; watch hypoglycemia |
| Adrenal suppression (chronic steroids) | Rare need for supplemental steroids for minor dentistry; major surgery/stress may need physician plan |
| Liver disease | Bleeding risk, altered drug metabolism; avoid excess acetaminophen/hepatotoxins |
| CKD | Dose-adjust renally cleared drugs; DOAC timing critical |
| Hyperthyroidism uncontrolled | Avoid elective care; epinephrine caution |
| Radiation to jaws | ORN risk with extractions—specialist pathways, HBO historically debated |
Drug–Drug Interaction Table (Dental Core)
| Combination | Risk |
|---|---|
| Warfarin + metronidazole / macrolides / azoles | ↑ INR, bleeding |
| DOAC + strong P-gp/CYP modulators | ↑ or ↓ anticoagulant effect (drug-specific) |
| Epinephrine + nonselective β-blockers | Possible exaggerated BP rise / reflex bradycardia (theoretical/clinical caution with large epi doses) |
| Epinephrine + TCA / cocaine | Arrhythmia risk—caution/avoid excess |
| Opioids + benzodiazepines / alcohol | Respiratory depression |
| NSAIDs + anticoagulants/antiplatelets | Bleeding; GI ulcer |
| Macrolides/azoles + midazolam | ↑ sedation (CYP3A4) |
| SSRI + tramadol | Seizure / serotonin syndrome risk |
Rapid review list
- Warfarin: recent INR + local hemostasis; often continue for simple surgery if therapeutic
- DOAC: timing and kidneys, not INR
- Never casually stop post-stent DAPT
- MRONJ: antiresorptives + surgery/infection; prevention first
- Pregnancy: treat infection; second trimester elective; tetracyclines out
- Metronidazole–warfarin and sedative stacking are classic interaction traps
Section 14.3 trains recognition of medical emergencies that these compromised patients are more likely to experience in the chair.
A patient taking warfarin for atrial fibrillation presents for simple extraction. INR yesterday was 2.3. Which management approach is most consistent with standard dental teaching?
Which statement about DOACs in dental care is most accurate?
A patient receiving monthly IV zoledronic acid for metastatic cancer needs a non-restorable tooth extracted. The most important risk to discuss related to antiresorptive therapy is:
Which prescribing choice is most appropriate when an odontogenic infection must be treated in pregnancy?